Kyverna Therapeutics (Kyverna Therapeutics) ROCE % : -50.35% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kyverna Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -50.35%.

Kyverna Therapeutics ROCE % Historical Data

The historical data trend for Kyverna Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics ROCE % Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-37.88

-46.30

-109.11

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial			-61.52	-80.76	-	-125.97	-50.35

Kyverna Therapeutics ROCE % Calculation

Kyverna Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-60.179	/	( ( (66.924 - 11.954)	+	(75.195 - 19.859) )	/ 2 )
	=	-60.179	/	( (54.97	+	55.336)	/ 2 )
	=	-60.179	/	55.153
	=	-109.11 %

Kyverna Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-106.596	/	( ( (75.195 - 19.859)	+	(389.984 - 21.865) )	/ 2 )
	=	-106.596	/	( ( 55.336	+	368.119 )	/ 2 )
	=	-106.596	/	211.7275
	=	-50.35 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Kyverna Therapeutics (NAS:KYTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kyverna Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024